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Abstract
Background: Using a live imaging approach, we have previously shown that microglia activation after stroke is
characterized by marked and long-term induction of the Toll-like receptor (TLR) 2 biophotonic signals. However, the
role of TLR2 (and potentially other TLRs) beyond the acute innate immune response and as early neuroprotection
against ischemic injury is not well understood.
Methods: TLR2−/− mice were subjected to transient middle cerebral artery occlusion followed by different
reperfusion times. Analyses assessing microglial activation profile/innate immune response were performed using in
situ hybridization, immunohistochemistry analysis, flow cytometry and inflammatory cytokine array. The effects of
the TLR2 deficiency on the evolution of ischemic brain injury were analyzed using a cresyl violet staining of brain
sections with appropriate lesion size estimation.
Results: Here we report that TLR2 deficiency markedly affects post-stroke immune response resulting in delayed
exacerbation of the ischemic injury. The temporal analysis of the microglia/macrophage activation profiles in TLR2−/−
mice and age-matched controls revealed reduced microglia/macrophage activation after stroke, reduced
capacity of resident microglia to proliferate as well as decreased levels of monocyte chemotactic protein-1 (MCP-1)
and consequently lower levels of CD45high/CD11b+ expressing cells as shown by flow cytometry analysis.
Importantly, although acute ischemic lesions (24 to 72 h) were smaller in TLR2−/− mice, the observed alterations in
innate immune response were more pronounced at later time points (at day 7) after initial stroke, which finally
resulted in delayed exacerbation of ischemic lesion leading to larger chronic infarctions as compared with wild-type
mice. Moreover, our results revealed that TLR2 deficiency is associated with significant decrease in the levels of
neurotrophic/anti-apoptotic factor Insulin-like growth factor-1 (IGF-1), expressed by microglia in the areas both in
and around ischemic lesion.
Conclusion: Our results clearly suggest that optimal and timely microglial activation/innate immune response is
needed to limit neuronal damage after stroke.
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Background
Increasing evidence suggests that post-ischemic inflam-
mation plays an important role in the evolution of brain
injury after ischemia. However, to what extent inflamma-
tory processes are deleterious and/or beneficial to brain
recovery is a matter of debate and controversy [1-5].
One of the key features of the brain inflammatory re-
sponse following ischemic injury is activation of the resi-
dent glial cells, including microglia. Activation of
microglial cells after stroke is characterized by marked
upregulation of the pattern-recognition receptors, such
as Toll like receptors (TLRs) [6-14]. TLRs have the abil-
ity to bind two types of ligands: (i) pathogen-associated
molecular pattern (PAMP) ligands in response to invad-
ing pathogens [15]; and (ii) endogenous danger-
associated molecular pattern (DAMP) ligands, recog-
nized in processes that present a threat to the structural
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integrity such as ischemic injury [12,16-19]. Recent evi-
dence suggests that TLRs, especially TLR2, may play a
key role in the evolution of brain damage following cere-
bral ischemia [9-11,20-23]. However, the exact role of
TLR2 in modulation of the post-ischemic inflammatory
response remains unclear. While previous studies were
primarily focused on the role of TLR2 only in the acute
phase 24 to 72 h after experimental stroke, the latter
phases of the tissue response to ischemia remained un-
explored [9,10,20,21,24]. Our recent work, using an
in vivo imaging approach, revealed that the TLR2 re-
sponse has a marked chronic component following brain
ischemia [11]. Therefore, the aim of the work presented
here was to investigate the role of TLR2 signaling and
microglial activation beyond the 24 to 72 h time
window.
Here, we report that TLR2 deficiency markedly affects
neuroinflammatory response to ischemic brain injury
resulting in altered post-ischemic inflammatory cell acti-
vation profiles, decreased proliferative capacity of resi-
dent microglia, reduced levels of MCP-1 and reduced
accumulation of CD45high/CD11b+ cells at the site of the
ischemic lesion. In addition, reduced levels of the neuro-
trophic and anti-apoptotic factor IGF-1 expressed by
microglial cells were observed in TLR2-deficient mice.
Importantly, cumulative effects of the altered post-
ischemic inflammatory response resulted in a late in-




All experiments were carried out on 2 to 4 month-old
male TLR2−/− mice obtained from Jackson Laboratories
(Bar Harbor, ME, USA), and wild-type (WT) C57BL/6 as
a control group. Experimental procedures were approved
by the Laval University Animal Care Ethics Committee
and are in accordance with The Guide to the Care and
Use of Experimental Animals of the Canadian Council
on Animal Care.
Surgical procedure
As previously described [3,11,25,26], unilateral transient
focal cerebral ischemia was induced by intraluminal fila-
ment middle cerebral artery occlusion (MCAO) for 1 h
followed by reperfusion periods of 1, 3, 4, 7 or 14 days.
Briefly, all animals were anesthetized with 2% isoflurane,
and body temperature was regularly checked and main-
tained at 37°C with a heating pad in order to avoid
hypothermia. After midline neck incision, the left com-
mon carotid artery and ipsilateral internal and external
carotid artery were exposed and isolated from surround-
ing tissue. A 12 mm long 6–0 silicon-coated monofila-
ment suture (Doccol, CA, USA) was inserted via the
proximal external carotid artery into the internal carotid
artery and then into the circle of Willis, thus occluding the
middle cerebral artery. After the occlusion period of 1 h
the monofilament suture was removed, followed by differ-
ent reperfusion periods. In our experiments we did not ob-
serve any increase in mortality in different experimental
groups and, in general, mortality was very low. The whole
operational procedure was conducted under the operating
microscope. All animals were allowed ad libitum access to
water and food before and after surgery.
Tissue collection
After different reperfusion periods, all animals were
anesthetized with an intraperitoneal injection of chloral
hydrate (150 mg/kg, 300–350 μl solution, concentration
10 mg/ml), and transcardially perfused with 30 ml 0.9%
saline, followed by ice-cold borax buffered 4% parafor-
maldehyde (PFA) at pH 9.5 (for in situ hybridization), or
PBS buffered 4% PFA at pH 7.4 (for immunohistochem-
istry, immunofluorescent labeling and cresyl-violet stain-
ing). Tissue samples were then post-fixed overnight in
4% PFA and equilibrated in PBS buffered 30% sucrose
for 48 h. Brains were embedded in Tissue-Tek (O.C.T.
compound, Sakura, CA ,USA), frozen at −20°C, cut into
35 μm thick coronal sections using cryostat, and stored
at −20°C.
In order to prepare samples for flow cytometric and
cytokine antibody array analysis, animals were anesthe-
tized with chloral hydrate and transcardially perfused
with ice-cold 0.9% saline to remove all blood from the
nervous tissue. Brain samples were surgically removed
and immersed in Hibernate-A medium (for flow cyto-
metric analysis), or immediately frozen in liquid nitrogen
(for cytokine antibody array analysis).
In situ hybridization
The expression and localization of TLR2 mRNA was
detected using S35 labeled riboprobes. Protocols for
probe synthesis and in situ hybridization were previously
described by Lalancette-Hebert and colleagues [3,11].
Immunofluorescence
Immunofluorescent labeling was performed on the brain
sections of TLR2−/− mice and WT C57BL6 mice, col-
lected 3 and 7 days after the MCAO procedure (all with
visible stroke region, n= 4 animals/group/stage), accord-
ing to the previously described procedure [3]. Briefly,
brain sections were blocked for 30 minutes in PBS con-
taining 10% goat serum and 0.25% Triton X-100. Sections
were then incubated overnight at room temperature with
primary antibody (1:250 mouse monoclonal anti-TLR2
(eBioscience, Burlington, Ontario, Canada), 1:500 rabbit
polyclonal anti-Iba1 (Wako, Richmond, VA, USA), 1:2000
rat monoclonal anti-CD68 (AbD Serotec, Oxford, UK),
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1:2000 rat polyclonal anti-BrdU (Axyll, Westbury, NY,
USA), 1:400 mouse monoclonal anti-BrdU Alexa Fluor
488 conjugated (Molecular Probes, Eugene, OR, USA),
1:500 rat anti-Mac2 (American Type Culture Collection,
Manassas, VA, USA), 1:400 rabbit polyclonal anti-cleaved
caspase-3 (Cell Signaling, Danvers, MA, USA), 1:300
mouse monoclonal anti-NeuN (Millipore, Billerica, MA,
USA), 1:1000 mouse monoclonal anti-glial fibrilary acidic
protein (GFAP) (Millipore Billerica, MA, USA), 1: 50 rat
monoclonal anti-CD11b (AbD Serotec) and 1:50 mouse
monoclonal anti-IGF-1 (Millipore)). Afterwards, sections
were incubated for 2 h at room temperature in corre-
sponding secondary antibody 1:500 (Invitrogen, Eugene,
OR, USA). Each of the steps above was followed by four 5
minute rinses in PBS-0.25% Triton X-100. At the end of
the procedure, sections were coverslipped with Fluoro-
mount G (Electron Microscopy Sciences, Fort Washing-
ton, PA, USA) and dried overnight.
Immunohistochemistry
Immunohistochemistry was performed according to the
previously described protocol [3,11]. Brain sections of
TLR2−/− and WT mice were collected 3, 7 and 14 days
after the MCAO procedure (all the stroke region, n = 4
brains/group). After an initial wash in PBS to remove O.
C.T., endogenous peroxidase activity was attenuated
with 0.6% hydrogen peroxide in PBS1X for 15 minutes.
Afterwards, sections were blocked for 1 h in PBS1X con-
taining 10% goat serum and 0.25% Triton X-100, and
incubated overnight with 1:400 rabbit anti-cleaved cas-
pase-3 antibody (Cell Signaling) in PBS1x containing
0.25% Triton X-100 and 5% goat serum. Sections were
then incubated for 2 h with 1:500 goat anti-rabbit bioti-
nylated secondary antibodies (Jackson ImmunoResearch,
West Grove, PA, USA). For the amplification of the
positive signal, incubation in avidin-biotin solution was
performed (Vectastain ABC kit, Vector Laboratories,
Burlingame, CA, USA). Staining was developed with
nickel-DAB solution (0.3%) (Vector Laboratories). Each
of the steps above was followed by four 5 minute rinses
in PBS-0.25% Triton X-100. At the end of the procedure,
sections were dehydrated and coverslipped with DPX
mounting medium (Electron Microscopy Sciences).
BrdU labeling
In order to visualize proliferating cells, mice were injected
intraperitoneally with 5-bromo-2′-deoxyuridine (BrdU)
(50 μg/g of mouse weight in saline) immediately before
the MCAO procedure and again 2, 24 and 48 h after sur-
gery. At 72 h after surgery, mice were anesthetized with
an intraperitoneal injection of chloral hydrate (150 mg/kg,
300–350 μl solution, concentration 10 mg/ml) and trans-
cardially perfused with 0.9% saline and PBS buffered 4%
PFA. Brains were isolated, post-fixed overnight in 4% PFA,
equilibrated in PBS buffered 30% sucrose for 48 h, and cut
into 35 μm thick coronal sections. Afterwards, pretreat-
ment was performed with 2.0 N HCl for protein hydrolysis
(30 minutes, 37.0°C) with further neutralization of HCl
with 0.1 M sodium borate (10 minutes), all diluted with
KPBS. Immunofluorescent labeling was later performed
on brain samples according to the standardized protocol
described above.
Flow cytometric analysis
In order to analyze the number of mononuclear cells
and their proliferation properties after ischemia, flow
cytometric analysis was performed on WT and TLR2−/−
mice at 3 and 7 days after MCAO. As previously
described [27,28], mice were injected intraperitoneally
with BrdU 12, 24 and 36 h prior to sacrifice, according
to BrdU Flow Kit protocol (BD, Franklin Lake, NJ, USA,
USA). Collected brain samples were prepared for flow
cytometric analysis according to previously described
procedures [27,28]. Briefly, tissue was mechanically dis-
sociated with a Teflon homogenizer and incubated with
1X HBSS containing papain (2 mg/ml) and DNase I
(0.025 U/ml) for 30 minutes at 37°C. Afterwards, cell
suspension was passed through 70 μm nylon cell strainer
(BD). In order to isolate the mononuclear cell fraction,
cell suspension was loaded in 30-37-70% isotonic Percoll
gradient (GE Healthcare, Uppsala, Sweden) and centri-
fuged for 40 minutes at 500 g. After centrifugation, an
interphase containing mononuclear cells was collected,
washed thoroughly, and stained with anti-CD45 conju-
gated with V500 (BD Horizon), and anti-CD11b conju-
gated with allophycocyanin (BD). Further, for
proliferation analysis, cells were stained with anti-BrdU
conjugated with fluorescin isothiocyanate antibody, fol-
lowing BrdU Flow Kit procedure (BD). Samples were
afterwards analyzed on a flow cytometer (BD LSRII) im-
mediately after the end of the staining protocol by a
‘blinded’ individual. Cells were gated using front scatter
and side scatter to eliminate unviable cells. Further gat-
ing was performed using side scatter and CD45 in order
to select the inflammatory cell population. Afterwards,
two-color analysis with the use of anti-CD11b and anti-
CD45 antibodies was performed in order to delineate
CD45low/CD11b+ (that is, microglial) and CD45high/
CD11b+ (that is, macrophage-like) cell populations
[27,28]. Proliferation analysis was performed using two-
color analysis of anti-CD11b and anti-BrdU antibodies.
Non-stroked, BrdU-treated animals were used as nega-
tive controls for proliferation analysis.
Cytokine array
The expression profile of inflammatory cytokines was
performed with a Mouse Cytokine Antibody Array (Ray-
bio Mouse Inflammation Antibody Array 1 (Cat#AAM-
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INF-1), RayBiotech, Norcross, GA, USA). As previously
described [3,29] , protein samples were obtained by
homogenization of TLR2−/− and WT brains 1 and 4 days
after MCAO (n= 3/group) in 1x cell lysis buffer that was
included in the RayBiotech kit (RaybioWMouse Inflam-
mation Antibody Array 1.1, Ray Biotech, #AAM-INF-
1 L). Protein lysates were obtained by homogenization of
brain of control and transgenic mice in 1X Cell Lysis
Buffer (included in the Ray Biotech kit) with Protease in-
hibitor cocktail (Sigma #P8340, St. Louis, MO, USA).
After extraction, samples were spun down and super-
natant was used for the experiment. The protein con-
centration was determined for each sample and diluted
at 300 μg total protein in 1x blocking buffer. For each
group (three mice per group) samples were pooled to-
gether and incubated with the array membrane over-
night at 4°C. After washing in the washing buffer
(included in the RayBiotech kit), membranes were incu-
bated with biotin-conjugated antibodies overnight. After
washing, membranes were incubated with horseradish
peroxidase conjugated streptavidin diluted in the block-
ing buffer for 2 h. Signal detection was performed
according to RayBiotech protocol, by exposing mem-
branes to x-ray film (Biomax MR1; #8701302; Kodak,
Rochester, NY, USA), and the obtained results analyzed
with ImageJ software.
Assessment of the infarct area
Every sixth coronal cryostat section of TLR2−/− and WT
mouse brains collected after reperfusion periods of 3, 7
and 14 days after MCAO (n=10/group) was stained with
cresyl-violet according to the standardized protocol, cov-
erslipped with DPX mounting medium (Electron Micros-
copy Sciences) and afterwards digitized. The area of
infarction (‘direct stroke area’) was quantified with the
ImageJ program (version 1.42q for Windows, National
Institutes of Health, USA), and the infarct volume was cal-
culated and expressed in mm3. As previously described
[10], correction for edema was applied for brains reper-
fused for 3 days by calculating the brain swelling. First, the
‘indirect stroke area’ was calculated as contralateral (non-
stroked) hemisphere area minus non-stroked area of the
ipsilateral (infarcted) hemisphere. A difference between
‘direct’ and ‘indirect’ stroke area represented brain swel-
ling. The correction of ‘direct stroke area’ was performed
by subtracting brain swelling volume from ‘direct stroke
area’. In addition, ‘indirect stroke area’ represents the vol-
ume of healthy tissue that correlates to the volume of is-
chemic tissue not affected by post-ischemic shrinkage.
Thus, ‘direct stroke area’ reflects lesion consolidation
(shrinkage) and glial scar formation and ‘indirect stroke
area’ represents lesion progression (that is, how does
altered inflammatory response reflect on surrounding-cell
survival and lesion dynamics).
Quantification and statistical analysis
Immunofluorescence
For the quantification of the immunofluorescent signal
(Iba1, CD68, BrdU, Mac2, IGF-1), four fields of view per
section (every sixth section, all stroke area), ten sections
per animal were acquired on a fluorescent microscope
(Leica DM5000B, Solms, Germany) using a 20x Plan
Fluotar objective. Immunoreactivity was quantified with
the ImageJ software by measuring the integrated optical
density (intensity of fluorescence per unit of surface
area), and results were expressed in arbitrary units as
previously described [3]. The data were averaged and
analyzed by a two-tailed unpaired Student’s t-test.
Immunohistochemistry
Every sixth sample section through the brain was used
for the immunohistochemical labeling with anti-cleaved
caspase-3 antibody. The number of positively stained
cells was estimated by the optical fractionator method
using a Nikon Eclipse 80i microscope equipped with
Stereo Investigator software. The ipsilateral (ischemic)
hemisphere was traced using a 4 Plan Apochromat and
sampled using 60 Plan Apochromat objectives (Nikon,
El Segundo, CA, USA). The counting parameters for the
experiments were the counting frame size (width and
height 100 × 100 μm), sampling grid (500 × 500 μm), dis-
sector height (10 μm) and the guard-zone thickness
(1.5 μm). Counts were performed on the entire ischemic
area of the ipsilateral (ischemic) hemisphere. Results
were expressed as number of cells per mm3 of ischemic
tissue. The data were averaged and statistically analyzed
by a two-tailed unpaired Student’s t-test.
Cytokine array
Cytokine expression assays were quantified by measur-
ing the optical density of each cytokine spot on the
membrane with ImageJ software, as previously described
[3,29]. Cytokines were presented on membranes as
duplicates and the analysis was performed twice. The
background values were subtracted from cytokine ex-
pression values. Data were expressed in arbitrary units
relative to appropriate positive control. Further, data
were averaged and analyzed by a two-tailed unpaired
Student’s t-test.
Results
Microglial cells upregulate Toll-like receptor 2 in response
to transient ischemic brain injury
To identify whether TLR2 is indeed upregulated in
microglial cells (at mRNA and protein levels) after
stroke we performed a series of in situ hybridization
experiments followed by double immunofluorescence
analysis. In accordance with previous studies [9,11,20],
24 h after stroke we observed a marked increase of the
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TLR2 mRNA in the area of ischemic lesion and the peri-
infarct zone, showing a positive S35 in situ hybridization
signal (Figure 1A). In contrast, no signal was observed in
the contralateral, unlesioned hemisphere (Figure 1B). As
shown in Figure 1C,D,E, double immunofluorescence
analysis of the brain sections after MCAO revealed a co-
localization of TLR2 staining with Iba1 (a common mar-
ker of microglial cells). The co-localization was observed
in activated microglial cells situated in ischemic and
peri-infarct regions of the brain at 3, 7 and 14 days post-
stroke, suggesting that microglia/macrophages upregu-
late TLR2 in early, as well as in more chronic phases, of
the brain response to ischemic injury (Figure 1C,D). As
previously reported [11], few neurons found within the
ischemic core area were positive for TLR2, while we did
not observe any co-localization between TLR2 and
GFAP-positive astrocytes (data not shown).
Toll-like receptor 2 deficiency alters microglia/
macrophage activation profiles
Because activated microglial activation in response to is-
chemic injury is characterized by a robust upregulation
of TLR2, we next investigated how and whether this
process may be affected in the context of TLR2 defi-
ciency. First, we analyzed expression levels of the dis-
tinct microglia/macrophage activation markers such as
Iba1 and CD68. The analyses were performed 3 and
7 days following transient MCAO. As expected, im-
munofluorescent labeling indicated a significant increase
of Iba1 immunoreactivity in the ischemic side of the
Figure 1 Microglial cells upregulate Toll-like receptor 2 in response to transient ischemic brain injury. (A, B) Photomicrographs of in situ
hybridization for Toll-like receptor (TLR) 2 mRNA in wild type (WT) mice 24 h after ischemic injury, indicating marked induction of TLR2 on the
ipsilateral side shown in low (A, left) and high (A, right) magnification, in contrast to the contralateral side where no positive S35 signal was
observed (B). (C, D, E) Double labeling 3, 7 and 14 days after transient middle cerebral artery occlusion (MCAO) reveals co-localization of TLR2
(green) and Iba1 (red) in WT mice, indicating that TLR2 are expressed almost exclusively by the microglia/macrophage cell population in both the
early and late phase of the response to ischemic brain injury. Scale bar: C, 50 μm.
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brain. The relative increase of Iba1 immunoreactivity (as
compared with unlesioned brain controls) was also
observed in TLR2-deficient mice. However, comparison
of the levels of microglial activation after stroke revealed
a marked reduction of Iba1 immunoreactivity in the
brain section of TLR2−/− mice as compared with WT
mice, at both 3 and 7 days after MCAO (Figure 2B).
Quantitative analysis of Iba1 staining revealed significant
reduction at 3 days (1.63-fold) as well as 7 days (1.36-
fold) after MCAO in TLR2−/− mice when compared
with WT mice (Figure 2C) (control: WT, 0.48 × 109 ±
0.16 × 109, n = 4; TLR2−/−, 0.54 × 109 ± 0.06 × 109, n = 4,
P= 0.438; 3 days: WT, 2.31 × 109 ± 0.12 × 109 , n = 4;
TLR2−/−, 1.41 × 109 ± 0.06 × 109, n = 4, P <0.001; 7 days:
WT, 8.67 × 109 ± 0.34 × 109, n = 4; TLR2−/−, 6.37 × 109 ±
0.26 × 109, n = 4, P= 0.002). Similar results were obtained
following analysis of CD68 immunoreactivity. As shown
in Figure 2D,E quantitative analysis of CD68 immunor-
eactivity revealed no significant difference at the lesion
site between WT and TLR2−/− mice 3 days after transi-
ent MCAO. Interestingly, however, CD68 immunoreac-
tivity was significantly decreased in TLR2−/− mice
7 days after MCAO, indicating a 1.52-fold reduction in
signal intensity (Figure 2E) (control: WT, 1.73 ×
109 ± 0.36 × 109, n = 4; TLR2−/−, 1.83 × 109 ± 0.48 × 109,
n = 4, P = 0.258; 3 days: WT, 4.65 × 109 ± 0.13 × 109;
TLR2−/−, 4.90× 109 ± 0.15× 109, n = 4, P=0.265; 7 days:
WT, 15.19 × 109 ± 0.47× 109, n = 4, TLR2−/−, 9.99× 109 ±
0.60× 109, n = 4, P <0.001).
Decreased levels of monocyte chemotactic protein-1
(MCP-1) and CD45high/CD11b+ cells in ischemic brains of
Toll-like receptor 2−/− mice
Evidence suggests that pro-inflammatory cytokines
such as IL-1β, IL-6 and TNFα may influence the ex-
tent of neuronal damage after cerebral ischemia [1,5].
To determine whether deficient microglial activation in
TLR2−/− mice after stroke (as shown in the results
above) induced changes in profiles of pro-inflammatory
cytokines, we used a standard mouse cytokine antibody
array technique to measure over 40 different cytokines
from ischemic brains of WT and TLR2−/− mice [3,29].
Because production of pro-inflammatory cytokines
peaks within 24 h following ischemic/reperfusion in-
jury (with the exception of transforming growth factor
β levels at 4 days), time points of 1 and 4 days post-
stroke were chosen for the analysis [30]. Ischemic in-
jury was associated with a robust increase in the pro-
duction of pro-inflammatory cytokines both in WT
and TLR2−/− mice. To our surprise, quantitative ana-
lysis revealed no significant changes in the levels of
pro-inflammatory cytokines such as IL-1β, IL-6 and
TNFα between the two experimental groups
(Figure 3A,B,C) (IL-1β at 1 day: WT, 0.026 ± 0.004,
n = 4; TLR2−/− 0.029 ± 0.002, n = 4, P= 0.602; at 4 days:
WT, 0.218 ± 0.002, n = 4; TLR2−/− 0.202 ± 0.004, n = 4,
P= 0.700; IL-6 at 1 day: WT, 0.016 ± 0.002, n = 4; TLR2
−/− 0.021 ± 0.001, n = 4, P= 0.082; at 4 days: WT,
0.011± 0.001, n = 4; TLR2−/− 0.009± 0.001, n = 4, P=
0.058; TNFα at 1 day: WT, 0.028± 0.003, n = 4; TLR2−/−
0.030± 0.001, n = 4, P=0.720; at 4 days: WT, 0.018±
0.001, n = 4; TLR2−/− 0.019 ± 0.001, n = 4, P=0.535).
Interestingly, however, we observed a significant de-
crease in the levels of MCP-1 1 day after MCAO
(Figure 4D) in TLR2−/− mice compared with their WT
controls (1 day: WT, 0.115 ± 0.002, n = 4; TLR2−/−
0.095 ± 0.002, n = 4, P= 0.026; 4 days: WT, 0.062 ± 0.007,
n = 4; TLR2−/− 0.059 ± 0.009, n = 4, P= 0.841). Because it
has been largely acknowledged that MCP-1 plays a piv-
otal role in monocyte recruitment to the site of injury, we
next investigated whether recruitment of infiltrating cells
may have been affected in the context of TLR2 deficiency.
One of the established protocols for evaluation of the
numbers of infiltrating monocytes and resident microglial
cells is based on the two-color quantitative and qualita-
tive flow cytometric analysis of CD45+/CD11b+ cell
populations [27,28]. Figure 3E presents a topographic
representation of the number of CD45high/CD11b+ cells
(that is, macrophage-like; red) and CD45low/CD11b+ cells
(that is, microglia; green) in the control (unlesioned)
hemisphere and in the ischemic hemisphere 3 and 7 days
after stroke in WT and TLR2−/− mice. As shown in
Figure 3F, quantitative analysis revealed a 2.26-fold re-
duction in numbers of CD45high/CD11b+ cells in ische-
mic brains of TLR2−/− mice 3 days after MCAO and a
2.02-fold reduction 7 days after MCAO compared with
WT mice (control: WT: 0.35 ± 0.12%, n = 4; TLR2−/−,
0.70 ± 0.30%, n = 4, P= 0.325; 3 days: WT, 21.08 ± 2.19%;
TLR2−/−, 9.34 ± 3.94%, n = 4, P= 0.040; 7 days: WT,
6.20 ± 0.86%; TLR2−/−, 3.06 ± 0.54%, n = 4, P= 0.210). We
next analyzed numbers of the resident microglial cells
after stroke. The quantitative flow cytometric analysis
indicated a significant 1.38-fold reduction in numbers of
the CD45low/CD11b+ cells in stroked brains of TLR2−/−
mice as compared with WT 7 days after stroke
(Figure 3G), suggesting a decrease in population of the
resident microglial cells. At 3 days after stroke the differ-
ence is not statistically significant, but a tendency to-
wards a reduced cell number (1.21-fold reduction) can be
observed in TLR2−/− mice compared with WT group
(control: WT: 5.71 ± 1.15%, n = 4; TLR2−/−, 6.23 ± 1.47%,
n = 4, P= 0.793; 3 days: WT, 20.44 ± 0.55%; TLR2−/−,
16.91 ± 2.26%, n = 4, P= 0.137; 7 days: WT, 32.44 ± 1.69%;
TLR2−/−, 23.55 ± 2.52%, n = 4, P= 0.026). Our results
suggest that early and selective downregulation of MCP-1
together with a significant decrease in the numbers of
CD45high/CD11b+ and CD45low/CD11b+ cells suggest
that TLR2 may have a role in the modulation of
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Figure 2 Toll-like receptor 2 deficiency leads to altered microglia/macrophage activation profiles. (A) Schematic representation of the
brain section used for the immunohistochemical experiments. Box represents the area magnified in B and D, and in Figure 3A,C,F,G, as well as in
Figures 6 and 7. (B) Representative photomicrographs of Iba1 immunoreactivity in control (unlesioned) wild-type (WT) and Toll-like receptor (TLR)
2−/− mice, as well as 3 and 7 days after transient middle cerebral artery occlusion (MCAO), indicate reduced accumulation of Iba1-positive cells in
TLR2 deficient mice. (C) Quantification of Iba1 immunoreactivity revealed significantly decreased immunoreactivity in TLR2−/− mice compared
with the WT group of mice 3 and 7 days after transient MCAO. (D) Photomicrographs of CD68 immunoreactivity in unlesioned (control) WT and
TLR2−/− mice 3 and 7 days after transient ischemic lesion. (E) Quantitative analysis of CD68 immunoreactivity in both groups reveals significant
reduction of the signal intensity 7 days after MCAO in the TLR2−/− group. Values (C, E) indicate mean± SEM (n = 4; **P <0.001 ***P <0.0001).
Scale bars: B, D: 100 μm.
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Figure 3 Decreased levels of MCP-1 and CD45high/CD11b+ expressing cells in Toll-like receptor 2 deficient mice. (A-C) Expression analysis
of inflammatory cytokines IL-1β, IL-6 and TNF-α on protein levels 1 and 4 days after transient middle cerebral artery occlusion (MCAO) revealed no
significant difference between wild-type (WT) and Toll-like receptor (TLR) 2−/− groups. (D) Significant reduction of MCP-1 levels in the TLR2−/− group
compared with their WT controls 1 day after transient MCAO. (E) Topographic representation of isolated brain mononuclear cells from ischemic
hemispheres of control, WT and TLR2−/− mice 3 and 7 days after stroke, analyzed using two-color flow cytometry. Cells were analyzed for CD45
and CD11b, thus allowing us to distinguish two different cell populations: CD45high/CD11b+ (that is, the macrophage-like) population (red); and
CD45low/CD11b+ (microglial) population (green). (F) Flow cytometric analysis showed a significant decrease in the number of CD45high/CD11b+ cells
in TLR2−/− mice compared with WT mice at both 3 and 7 days after stroke. (G) Quantitative analysis of CD45low/CD11b+ cells (microglia) indicates a
significant reduction in cell numbers in TLR2−/− mice as compared with WT 7 days after stroke, while 3 days after stroke the difference is not
significant, but there is a tendency toward reduced cell numbers in TLR2−/− mice. Values (A-D) are expressed as mean±SEM (n=4, *P <0.05).
Data (F, G) are expressed as percentage of CD45+ events ± SEM (n= 4; *P <0.05).
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monocyte/brain macrophage recruitment to the site of is-
chemic injury.
Reduced proliferation of resident microglial cells in
ischemic brains of Toll-like receptor 2 deficient mice
A highly characteristic feature of the injury-induced
microglial activation is massive, but usually transient, ex-
pansion of microglial cell population, peaking 48 to 72 h
after initial insult [3,31]. Our results suggest a decrease
in resident microglia numbers. However, at present, it is
unclear to what extent the ischemic injury-induced
microglial proliferation is affected in the context of
TLR2 deficiency. To address this issue, the TLR2−/− and
WT mice were injected daily with BrdU. The BrdU-posi-
tive/proliferating cells were quantified 3 and 7 days after
stroke. In agreement with previous results, quantitative
analysis of the BrdU staining (Figure 4A,B) revealed a
robust increase in BrdU immunoreactivity in WT mice.
As revealed in Figure 4B, we observed a 24.55% reduc-
tion in cell proliferation in TLR2−/− mice (control: WT,
0.03 × 108 ± 0.01 × 108, n = 4; TLR2−/−, 0.04 × 108 ± 0.01 ×
108, n = 4, P= 0.278; 3 days: WT, 4,97 × 108 ± 0,13 × 108;
TLR2−/−, 3,75 × 108 ± 0,42 × 108, n = 4, P= 0.048). To
further confirm that BrdU is indeed expressed in prolif-
erating microglial cells, double immunofluorescence for
BrdU and Iba1 (markers of cell proliferation and micro-
glia/macrophages, respectively) 3 days after transient
MCAO was performed. As expected, results demon-
strated that the majority of BrdU-positive cells were also
positive for Iba1 staining (Figure 4C). To increase the
resolution of the results obtained by BrdU signal inten-
sity measurement the microglial proliferative capacity in
TLR2−/− mice was assessed by flow cytometry measure-
ment. Proliferation analysis was carried out on the popu-
lation of CD45low/CD11b+ cells (microglial population)
[27,28] obtained from TLR2−/− and WT animals
injected with BrdU (Figure 4D). The flow cytometric
analysis 3 days after stroke revealed a robust, 10-fold in-
crease in the number of CD45low/CD11b+/BrDU+ cells
in WT mice (Figure 4D,E). As further shown in
Figure 4E, quantitative analysis revealed a significant
(55.91%) reduction in the number of proliferating
CD45low/CD11b+ cells in TLR2−/− compared with WT
mice (control (contralateral): WT, 1.72 ± 0.78%, n = 4;
TLR2−/−, 1.39 ± 0.63%, n = 4, P= 0.762; 3 days: WT,
18.51 ± 1.41%; TLR2−/−, 8.16 ± 2.14%, n = 4, P= 0.014).
The number of proliferating cells declined by day 7 and
there were no significant differences in the numbers of
CD45low/CD11b+/BrDU+ cells between the two experi-
mental groups (Figure 4E).
Previously we have shown that the injury-activated
resident microglial cells in proliferation upregulate
galectin-3 (a Mac-2 marker of activated microglia) [3].
Further characterization of the proliferating cells in our
experimental model revealed that approximately 80% of
BrdU positive cells co-localize with Mac-2 (Figure 4F).
Interestingly, analysis of the Mac-2 immunoreactivity
revealed a significant 40.52% reduction in the signal in
TLR2−/− compared with WT mice (Figure 4G,H) (con-
trol (contralateral): WT, 0.06 × 109 ± 0.03 × 109, n = 4;
TLR2−/−, 0.03 × 109 ± 0.01 × 109, n = 4, P= 0.448; 3 days:
WT, 4,17 × 109 ± 0,20 × 109; TLR2−/−, 2,48 × 109 ± 0,75 ×
109, n = 4, P= 0.019). Altogether, the obtained results in-
dicate that TLR2 deficiency may affect ischemic injury-
induced proliferation of the resident microglial cells.
Toll-like receptor 2 deficiency increases delayed neuronal
apoptosis and exacerbates ischemic injury
We have demonstrated that activated/proliferating and
galectin-3-positive microglial cells exert neuroprotective
properties by secreting IGF-1 [3]. To date, it is unclear
whether defective microglial activation/proliferation after
stroke may affect evolution of the ischemic injury in
TLR2-deficient mice. Although previous studies have
reported smaller acute ischemic lesions in TLR2-
deficient mice and/or in mice treated with TLR2 block-
ing antibodies, the analysis has been limited to the first
24 to 72 h after stroke [9,10,20,21]. We next asked
whether initial neuroprotection against ischemic injury
in TLR2−/− mice is also extended to later time points
(See figure on previous page.)
Figure 4 Toll-like receptor 2 deficient mice display reduced proliferation of resident microglial cells. (A) Photomicrographs of BrdU
immunoreactivity in wild-type (WT) and Toll-like receptor (TLR) 2−/− mice 3 days after transient middle cerebral artery occlusion (MCAO) and
their unlesioned controls, respectively. (B) Quantification of BrdU immunoreactivity indicates reduced cell proliferative capacity in TLR2−/− mice
compared with WT mice 3 days after transient MCAO. (C) Representative photomicrographs of double immunostaining on WT brain sections
3 days after transient MCAO show almost complete co-localization of BrdU (green) positive cells with Iba1 (red; white arrows). (D) Flow
cytometric analysis of the CD45low/CD11b+ (microglial) population proliferation in WT and TLR2−/− mice 3 days after MCAO compared with their
contralateral (unlesioned) hemisphere controls. (E) Graph presents quantification of microglial proliferation measured by flow cytometric analysis.
Data indicate reduced microglial proliferation in TLR2−/− mice compared with WT mice 3 days after MCAO. (F) Double immunofluorescent
labeling reveals co-localization of BrdU (green) and Mac-2 (red; white arrows) in WT brain sections 3 days after transient MCAO. (G)
Representative photomicrographs of Mac-2 immunofluorescence in WT and TLR2−/− mice observed 3 days after transient MCAO. (H)
Quantification of Mac-2 immunoreactivity 3 days after transient MCAO revealed reduced signals in TLR2−/− mice compared with WT mice. Data
(B, H) are indicated as mean± SEM (n = 4; *P <0.05). Data (E) are expressed as percentage of CD45+ events ± SEM (n = 4; *P <0.05). Scale bars: A, G,
100 μm; C, F, 50 μm.
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after stroke. Quantification of the ischemic lesions was
performed using cresyl violet stained brain sections of
TLR2−/− mice and their WT controls (n = 10/group) 3,
7 and 14 days after MCAO. As expected, TLR2−/− mice
showed significantly reduced direct stroke area (37.03%)
compared with WT mice 3 days after MCAO
(Figure 5A,5B), which is in accordance with previous
reports [20,21]. As described in detail in the Methods
section and previously reported [10], we analyzed “indir-
ect stroke area” as a measure of contralateral (non-
stroked) hemisphere area minus non-stroked area of the
ipsilateral (infarcted) hemisphere. The difference be-
tween ‘direct’ and ‘indirect’ stroke area represented brain
swelling. The correction of ‘direct stroke area’ was then
performed by subtracting brain swelling volume from
‘direct stroke area’. In addition, ‘indirect stroke area’
represents the volume of healthy tissue that correlates to
the volume of ischemic tissue not affected by post-
ischemic shrinkage. Thus, ‘direct stroke area’ reflects le-
sion consolidation (shrinkage) and glial scar formation,
while ‘indirect stroke area’ represents lesion progression
(that is, the effect of altered inflammatory response on
lesion dynamics). In that way, ‘direct’ and ‘indirect’ stroke
area represent important parameters for adequate
characterization of more chronic time points.
To our surprise, 7 days after transient MCAO, the size
of direct stroke area in TLR2−/− mice increased and
was significantly larger (31.87%) when compared with
controls. Due to a post-ischemic consolidation of the is-
chemic brain tissue and glial scar formation in the later
phase (14 days after transient MCAO), direct stroke area
of WT and TLR2−/− mice were reduced compared with
3 and 7 days after MCAO. Still, direct stroke area
remained significantly larger in TLR2−/− mice when
compared with the WT control group (27.99%) (3 days:
WT, 57.92 ± 4.98, n = 10; TLR2−/−, 36.47 ± 3.58, n = 10,
Figure 5 Toll-like receptor 2 deficiency delays evolution of ischemic brain lesion. (A) Representative low-magnification photomicrographs
of cresyl violet stained brain sections of wild type (WT) and Toll-like receptor (TLR) 2−/− mice 3, 7 and 14 days after transient middle cerebral
artery occlusion (MCAO). The ischemic area is emphasized by a black dashed line. (B) Significantly reduced direct stroke area in TLR2−/− mice
3 days after transient MCAO compared with WT mice. This was followed by marked lesion exacerbation in TLR2−/− mice 7 days after injury, while
lesions in WT mice showed a reduction in size. The evolution of direct stroke area stagnated 14 days after injury, indicating significantly larger
final lesion size in TLR2−/− mice compared with the WT group. (C) A smaller indirect stroke area in TLR2−/− mice compared with WT mice
3 days after transient MCAO. In contrast, 7 days after injury, indirect stroke area in the TLR2−/− group was larger compared with WT mice, and
the same relationship was observed 14 days after ischemic injury. Values are expressed as mean± SEM (n = 10, *P <0.05, **P <0.001).
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P= 0.003; 7 days: WT, 39.00 ± 2.78, n = 10; TLR2−/−
51.43 ± 3.47, n = 10, P= 0.012; 14 days: WT, 22.15 ± 0.96,
n = 9; TLR2−/− 28.35 ± 2.09, n = 6, P= 0.010). Quantita-
tive assessment of indirect stroke area (volume of
healthy tissue that correlates to volume of damaged, is-
chemic tissue not affected by post-ischemic consolida-
tion and glial scar formation) 3 days after transient
MCAO revealed a significant reduction of indirect
stroke area (37.58%) in TLR2−/− mice compared with
the control WT group (Figure 5A,C). In addition, 7 days
after transient MCAO, indirect stroke area was signifi-
cantly larger (26.41%) in the group of TLR2−/− mice
compared with controls. In the later phase (14 days after
transient MCAO), evolution of the ischemic lesion stag-
nated, and indirect stroke area in TLR2−/− mice
remained significantly larger (29.07%) compared with
the WT control group (3 days: WT, 57.82 ± 5.04, n = 10;
TLR2−/−, 36.09 ± 4.04, n = 10, P= 0.004; 7 days: WT,
42.29 ± 3.24, n = 10; TLR2−/− 53.46 ± 2.19, n = 10, P=
0.010; 14 days: WT, 44.10 ± 3.08, n = 9; TLR2−/−
56.92 ± 5.43, n = 6, P= 0.049). Altogether, these results
indicate that TLR2 deficiency induces delayed exacerba-
tion in the size of the ischemic lesion.
Next, we investigated whether the late increase in the
size of ischemic lesions detected in TLR2−/− mice is
associated with an increase in delayed neuronal cell
death. The number of apoptotic cells in both groups was
determined using immunohistochemical labeling with
anti-cleaved caspase-3 antibody 3, 7 and 14 days after
transient MCAO. As shown in Figure 6A,B, the number
of apoptotic cells 3 days after transient MCAO showed a
1.35-fold reduction in TLR2−/− mice compared with the
control WT group, suggesting an early neuroprotective
effect of TLR2 deficiency. However, consistent with a
delayed increase in the size of ischemic lesions, at 7 days
after transient MCAO the number of cleaved caspase-3-
positive cells per mm3 of infarcted volume in TLR2−/−
mice showed a 1.37-fold increase compared with the
group of WT mice. At 14 days after transient MCAO, the
number of cleaved caspase-3-positive cells remained
higher in the TLR2−/− group compared with the WT
group, although not significantly higher due to a large
variation in the number of apoptotic cells in the TLR2−/−
group (3 days: WT, 2.52× 105 ± 0.15× 105, n = 4; TLR2−/−,
1.87× 105 ± 0.18× 105, n = 4, P=0.046; 7 days: WT,
2.99× 105 ± 0.27× 105, n = 4; TLR2−/−, 4.11× 105 ± 0.35×
105, n = 4, P= 0.046; 14 days: WT, 4.81× 105 ± 0.21× 105,
n=4; TLR2−/−, 5.92×105±0.72×105, n=4, P=0.2128). In
order to investigate which cell types underwent apoptosis,
double immunofluorescence labeling of cleaved caspase-3
and the neuronal marker NeuN, the astrocyte marker
GFAP, and the microglia/macrophage marker CD11b was
performed on brain sections of WT mice 3 days after tran-
sient MCAO (Figure 6C,D,E). The cleaved caspase-3 signal
co-localized to a great degree (>90%) with the neuronal
marker NeuN (Figure 6C). As revealed in Figure 6E, only a
few caspase-3-positive cells were also positive for the
microglia/macrophage marker CD11b. We did not observe
co-localization of cleaved caspase-3 immunostaining with
the astrocyte marker GFAP (Figure 6D). Hence, delayed ex-
acerbation of ischemic injury in TLR2−/−mice is character-
ized by a delayed increase in neuronal apoptosis.
Reduced levels of Insulin-like growth factor 1 in brains of
Toll-like receptor 2 deficient mice after transient ischemia
Previous findings demonstrated that activated and pro-
liferating microglial cells produce neurotrophic/anti-
apoptotic factors such as IGF-1 and thus exert neuro-
protection [3,32,33]. Because our results demonstrated
reduced proliferating capacity/decrease in numbers of
microglial cells in TLR2−/− mice, we hypothesized that
IGF-1 levels may have been affected in TLR2 deficiency
which may have resulted in an increase in delayed neur-
onal death. To test our hypothesis, we measured IGF-1
levels in control (unlesioned) and lesioned hemispheres of
WT and TLR2−/− mice (Figure 7A,B). Analyses were per-
formed 3 and 7 days following transient ischemia. As
expected, immunofluorescence labeling indicated a signifi-
cant increase of signal intensity between control (unle-
sioned) and lesioned hemispheres in WT and TLR2−/−
mice. Interestingly, quantitative analysis of the IGF-1 sig-
nal revealed a significant 1.42-fold reduction at 3 days and
a 2.73-fold reduction at 7 days after MCAO in TLR2−/−
mice when compared with the WT mice group
(Figure 7B) (control (contralateral): WT, 0.004× 109 ±
0.001 × 109, n = 4; TLR2−/−, 0.006 × 109 ± 0.001 × 109,
n = 4, P = 0.283; 3 days: WT, 1.24 × 109 ± 0.11 × 109;
TLR2−/−, 0.87× 109 ± 0.04× 109, n = 4, P=0.039; 7 days:
WT, 2.32× 109 ± 0.29× 109, n = 4, TLR2−/−, 0.85× 109 ±
0.13× 109, n = 4, P= 0.004). To further confirm that the
cells expressing IGF-1 after transient ischemia are micro-
glia, double labeling with the marker Iba1 was performed
3 and 7 days after stroke. IGF-1 expression on the ische-
mic site was almost exclusively due to microglia/macro-
phages (Figure 7C,D), which is in agreement with
previous studies [3,33]. The same results were obtained
on stroked tissues of TLR2−/− mice (data not shown). No
cell-specific immunostaining was detected for astrocytes
or neurons in WT or TLR2−/− at both time points on the
ischemic lesion site (data not shown). Altogether, these
results suggest that the defective immune response in the
brain caused by TLR2 deficiency resulted in a reduced
amount of microglia-secreted IGF-1 (a very potent anti-
apoptotic molecule for stressed neurons) in and around
the ischemic lesion site which may have caused an in-
crease in delayed neuronal death and consequent exacer-
bation of the ischemic injury observed in TLR2-deficient
mice.
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Figure 6 Delayed exacerbation of neuronal apoptosis in Toll-like receptor 2 deficient mice. (A) Photomicrographs of cleaved caspase-3
immunoreactivity in wild-type (WT) and Toll-like receptor (TLR) 2 −/− mice 3,7 and 14 days after transient middle cerebral artery occlusion
(MCAO). (B) Quantification of labeled cells showed a higher number of apoptotic cells in WT compared with TLR2−/− mice 3 days after injury,
while 7 days after injury the number of cleaved caspase-3-positive cells was significantly higher in the TLR2−/− group compared with the WT
group of mice. The number of cleaved caspase-3-positive cells was higher in TLR2−/− mice 14 days after transient MCAO, but not significantly
because of high variation within the group. (C) Double immunofluorescence analysis reveals a high proportion of cleaved caspase-3 (green)
positive cells correlating with the neuronal marker NeuN (red, co-localization marked with white arrows). (D) No co-localization was observed for
GFAP (red) and cleaved caspase-3 (green). (E) Only a few cleaved caspase-3-positive cells (green) showed co-localization with Iba1 (red, co-
localization marked with white arrow heads), while the vast majority were not co-localizing. Data (B) are expressed as mean± SEM (n = 4, *P <0.05,
**P <0.001). Scale bars: A, C, D, E, 25 μm.
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Discussion
Microglial activation and innate immune response are
key features of the brain inflammatory response to ische-
mic injury. Using a live imaging approach we have previ-
ously shown that microglial activation after stroke is
characterized by a marked long-term induction of the
TLR2 signals, thus suggesting an important role of TLR2
signaling in brain ischemia. In the present study, we re-
port altered microglia activation profiles and delayed ex-
acerbation of ischemic injury in the mouse model
lacking functional TLR2 receptors. Namely, the TLR2
deficiency resulted in: (1) reduced microglia/macrophage
activation after stroke; (2) reduced capacity of resident
microglia to proliferate; and (3) decreased levels of
MCP-1 and consequently lower levels of CD45high/
CD11b+ expressing cells. Importantly, although acute is-
chemic lesions (24 to 72 h) were smaller in TLR2−/−
mice, the observed alterations in the innate immune re-
sponse were more pronounced at later time points (at
day 7) after initial stroke, which finally resulted in
delayed exacerbation of the ischemic lesion leading to
larger chronic infarctions as compared with WT mice.
Finally, reduced microglial activation/proliferation
resulted in a significant decrease in expression of IGF-1
in microglial cells after stroke. Altogether, our results
clearly suggest that optimal and timely microglial activa-
tion/innate immune response is needed to limit the ex-
tent of neuronal damage after stroke.
Upon activation, microglial cells start to express TLRs
on their surface [11,34,35]. The functional role of TLRs
is the signal transduction into the cell via TLR domain-
containing adaptor proteins and MyD88 adaptor protein
resulting in degradation of IκB proteins and transloca-
tion of transcription factor NFκB into the nucleus, which
induces expression of proinflammatory cytokines in re-
sponse to PAMPs and DAMPs [5,36,37]. Among diverse
TLRs, it has been reported that, after transient cerebral
ischemia, induction of TLR2 predominates among TLRs,
followed by TLR4 and TLR9 [9]. After brain injury and/
or pathogen exposition, TLR2 is mainly expressed in the
population of microglial cells [11,20,38,39]. In addition,
some reports indicate expression of TLR2 in astrocytes,
oligodendrocytes and ependymal cells, as well as neu-
rons and neuronal progenitor cells [12,18,40,41]. Our
results revealed a marked induction of TLR2 (at the
mRNA and protein level) that was restricted to ischemic
lesion and peri-infarct zones. No signal was observed
contralaterally, that is on the non-stroke side. Further,
our analysis revealed that, in early and late phases of the
brain response to transient ischemia, upregulation of
TLR2 occurred almost exclusively on activated micro-
glial cells (see Figure 1C,D,E). Minor expression was
found in a limited subpopulation of neurons situated in
the ischemic core area and we did not observe any co-
localization between TLR2 and GFAP-stained astrocytes.
These results are in agreement with previous reports on
TLR2 induction following brain injury from ours [11]
and other laboratories [9,20,21,23,40,42].
As discussed, previous studies reported initial neuro-
protection against ischemia in TLR2−/− mice [9,20,21].
In keeping with previous work, the results of our study
revealed and confirmed that, in TLR2−/− mice, the early
post-stroke period (up to 3 days after transient MCAO)
is characterized by smaller infarcts (see Figure 5). Inter-
estingly, however, initial neuroprotection was not
extended to later time points and we observed progres-
sive and delayed exacerbation of neuronal damage in
TLR2-deficient mice. Thus, in TLR2-deficient mice an
early reduction in microglial response was associated
with initially smaller lesions; a long-term decrease in
microglia/macrophage activation and proliferation led to
increased neuronal apoptosis and delayed exacerbation
of ischemic lesion (Figures 2, 3, 4, 5 and 6). Previous
work suggests that some inflammatory molecules may
have time-dependent functions [43]; however, the role of
TLR2 (and potentially other TLRs) beyond the acute in-
nate immune response in ischemic injury is not well
understood. The results presented in this study suggest
that TLR2 has a role in injury-induced monocyte/macro-
phage recruitment as well as in colony proliferation.
Increased activation and accumulation of the myeloid
cells on the site of the lesion after stroke may occur ei-
ther due to massive proliferation of resident microglia,
which normally peaks 48 to 72 h after initial activation,
or due to increased monocyte recruitment from the cir-
culation to the lesion site [3,31,44,45]. Our data suggest
that both processes may have been affected in TLR2−/−
mice. We detected a selective decrease in MCP-1 levels
1 day after stroke and consequently lower numbers of
CD45high/CD11b+ expressing cells at both 3 and 7 days
after the onset of ischemia. In addition, TLR2 deficiency
was associated with the reduced capacity of resident
(See figure on previous page.)
Figure 7 Reduced levels of Insulin-like growth factor 1 in brains of Toll-like receptor 2 deficient mice after stroke. (A) Photomicrographs
of (IGF)-1 immunoreactivity in control (unlesioned) and lesioned brain hemispheres at 3 and 7 days after stroke, showing reduced levels of IGF-1
immunoreactivity in Toll-like receptor (TLR) 2−/− mice. (B) Quantification of signal intensity indicates a reduced level of IGF-1 present in the
brains of TLR2−/− mice following transient ischemia compared with wild-type (WT) mice. (C, D) Double immunofluorescence labeling reveals
that IGF-1 expression was present in microglia/macrophages within and around the infarcted region in both 3 and 7 days after ischemia. Data (B)
are indicated as mean± SEM (n = 4; *P <0.05, **P <0.001). Scale bars: A, 100 μm; C, D: 50 μm.
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microglial cells to proliferate. Reduced microglial prolif-
eration was observed in stroked brains of TLR2−/− mice
3 days after MCAO. Although at present we cannot ex-
clude the possibility that the detected decrease in micro-
glial proliferation may be due to initially smaller infarcts,
it is important to mention that the size of infarction did
increase over time in TLR2−/− mice; however, this was
not accompanied by an increase in microglial prolifera-
tive response and/or activation. As shown by flow cyto-
metric analysis, the proliferative response stayed low in
TLR2−/− mice 7 days after stroke (see Figure 4). On the
other hand, a decrease in CD45high/CD11b+ expressing
cells observed at days 3 and 7, and a selective decrease
in MCP-1 observed in TLR2−/− mice, suggest that
TLR2 signaling is needed for adequate recruitment of
circulating monocytes. Taken together, these results sup-
port in part the hypothesis established on the axonal in-
jury model which suggests that, in the acute phase,
TLR2 may modulate proliferation rather than the entry
of circulating monocytes [23,31,46-48].
The question that arises here is how to correlate deficient
monocyte/microglia responses observed in TLR2−/− mice
with delayed exacerbation of the ischemic injury. One of
the possibilities is that, as previously reported, rapid phago-
cytic removal of dead or dying cells prevents the release of
proinflammatory intracellular components and contributes
to the resolution of inflammation [49]. Reduced CD68 sig-
nal intensity may suggest a reduced number of phago-
somes present on the lesion site in TLR2−/− mice, thus
implying that the engulfment of cellular debris is altered
with a consequently prolonged inflammation. It is note-
worthy that altered microglia/macrophage activation pro-
files observed in TLR2−/− mice were more pronounced at
day 7 post-stroke, which coincided with the initial enlarge-
ment of ischemic lesions in TLR2-deficient mice. An add-
itional explanation as suggested by our results is that a
defective innate immune response in the brain caused by
TLR2 deficiency results in deficient microglia proliferation
and consequently reduced levels of IGF-1, which may lead
to an increase in delayed neuronal death and exacerbation
of ischemic injury.
Based on our results, we may conclude that reduction
in numbers as well as aberrant profiles of the activated
microglia/macrophages may over time result in a micro-
environment that is detrimental for neuronal survival
and causes exacerbation of ischemic lesions.
Conclusion
Taken together, our data suggest that functional TLR2
signaling is required for modulation of microglia/macro-
phage responses in the injured brain. Moreover, our data
also indicate that TLR2 induction may exert temporally
differential effects. However, the ischemic injury-induced
TLR2 response in the brain is instrumental for timely
resolution of the post-ischemic inflammation, finally lim-
iting exacerbation and/or propagation of the initial
ischemia-induced neuronal damage.
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